Mediwound (NASDAQ: MDWD) has recently received a number of price target changes and ratings updates:

  • 11/25/2017 – Mediwound was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
  • 11/21/2017 – Mediwound was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel. “
  • 11/16/2017 – Mediwound was given a new $9.00 price target on by analysts at SunTrust Banks, Inc.. They now have a “buy” rating on the stock.
  • 11/16/2017 – Mediwound was given a new $10.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 10/20/2017 – Mediwound was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
  • 10/17/2017 – Mediwound was given a new $10.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.

Shares of Mediwound Ltd (NASDAQ MDWD) opened at $4.60 on Thursday. Mediwound Ltd has a twelve month low of $4.15 and a twelve month high of $8.25.

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Receive News & Ratings for Mediwound Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound Ltd and related companies with MarketBeat.com's FREE daily email newsletter.